BeOne Medicines director plans $47M ADS sale

BeOne Medicines Ltd. (ONC) received a notice that Xiaodong Wang, identified as a director and chair of its Scientific Advisory Board, plans to sell up to 131,370 ADS under Rule 144 through a broker on or after September 8, 2026.

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) received a notice that Xiaodong Wang, identified as a director and chair of its Scientific Advisory Board, plans to sell up to 131,370 ADS under Rule 144 through a broker on or after September 8, 2026.

The planned sale consists of 124,110 ADS to be received upon exercise of stock options over the next three months and 7,260 ADS acquired upon vesting of restricted stock units between June 22, 2022 and June 15, 2026. The aggregate market value of the ADS to be sold is stated as $47,064,616.20, with 57,914,782 ADS outstanding.

Key Figures

ADS to be sold: 131,370 ADS Aggregate market value: $47,064,616.20 ADS outstanding: 57,914,782 ADS +4 more

7 metrics

ADS to be sold 131,370 ADS Maximum number of ADS covered by the Rule 144 notice

Aggregate market value $47,064,616.20 Stated market value of the 131,370 ADS to be sold

ADS outstanding 57,914,782 ADS Number of ADS outstanding referenced in the notice

ADS from stock options 124,110 ADS Securities to be sold, to be received upon exercise of stock options over the next three months

ADS from RSU vesting 7,260 ADS Securities to be sold acquired upon RSU vesting from June 22, 2022 to June 15, 2026

Planned sale date September 8, 2026 Date listed for the proposed sale of ADS

Date of notice September 8, 2026 Date on which the Form 144 notice is dated

Key Terms

Rule 144, ADS, Exercise of Stock Options, Restricted Stock Units

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

ADS financial

"ADS | Morgan Stanley Smith Barney LLC Executive Financial Services"

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

Exercise of Stock Options financial

"ADS | 09/08/2026 | Exercise of Stock Options | Issuer"

Restricted Stock Units financial

"ADS | 06/22/2022 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

What does the Form 144 filing disclose for BeOne Medicines Ltd. (ONC)?

The filing states that Xiaodong Wang, a director and chair of the Scientific Advisory Board, intends to sell up to 131,370 ADS of BeOne Medicines Ltd. under Rule 144, through a broker, with a stated aggregate market value of $47,064,616.20.

How many BeOne Medicines (ONC) ADS are planned to be sold and from what sources?

The notice covers up to 131,370 ADS, including 124,110 ADS to be received upon the exercise of stock options over the next three months and 7,260 ADS that were acquired upon the vesting of restricted stock units from June 22, 2022 through June 15, 2026.

What is the stated market value of the BeOne Medicines (ONC) ADS covered by this Form 144?

The Form 144 lists an aggregate market value of $47,064,616.20 for the 131,370 ADS proposed to be sold. It also notes that 57,914,782 ADS were outstanding, providing context for the relative size of the planned sale.

When were the BeOne Medicines (ONC) securities to be sold acquired?

According to the notice, the 124,110 ADS will be received upon stock option exercises, with acquisition and payment dates corresponding to each exercise/sale over the next three months. The 7,260 ADS were acquired upon RSU vestings between June 22, 2022 and June 15, 2026.

Who is the seller named in the BeOne Medicines (ONC) Form 144 and what is their role?

The person for whose account the securities are to be sold is Xiaodong Wang, identified as a Director and Chair, Scientific Advisory Board of BeOne Medicines Ltd. The filing provides this role information in connection with the planned Rule 144 sale.

What broker and trading venue are indicated for the BeOne Medicines (ONC) ADS sale?

The Form 144 lists Morgan Stanley Smith Barney LLC Executive Financial Services, New York, as broker for the ADS, and identifies NASDAQ as the market on which the ADS are traded, with an indicated sale date of September 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:26 PM Accepted by SEC EDGAR 09/08/2026 - 04:26 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001662982
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BEONE MEDICINES LTD
SEC File Number	001-37686
Address of Issuer	Aeschengraben 27 Basel SWITZERLAND 4051
Phone	41616851900
Name of Person for Whose Account the Securities are To Be Sold	XIAODONG WANG
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Chair
Relationship to Issuer	Scientific Advisory Brd

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	131370	47064616.20	57914782	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	09/08/2026	Exercise of Stock Options	Issuer			124110	09/08/2026	Cash
ADS	06/22/2022	Restricted Stock Units	Issuer			7260	06/22/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The 124,110 securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale. The 7,260 securities to be sold were acquired upon the vesting of restricted stock units during the period of 06/22/2022 through 06/15/2026.
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/09/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Xiaodong Wang
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)